Hepatosplenic T-Cell Lymphoma
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DIS-HSTCL |
|---|---|
| Type | Disease |
| Aliases | HSTCLγδ T-cell lymphoma hepatosplenic typeГепатоспленічна T-клітинна лімфома |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 9716/3 |
|---|---|
| icd_10 | C84.7 |
| who_classification | Mature T-cell and NK-cell neoplasms — Hepatosplenic T-cell lymphoma per WHO 5th ed. |
Notes
STUB. Bone marrow + spleen biopsy diagnostic; LN biopsy often negative. γδ TCR + i(7q) — defining. Refractory to CHOP-style; ICE / IVAC or HD-ara-C / platinum-based induction. Allo-SCT from a matched donor — the only curative option.
Used By
Algorithms
ALGO-HSTCL-1L- ALGO-HSTCL-1L
Indication
IND-HSTCL-1L-CHOEP-UNFIT- IND-HSTCL-1L-CHOEP-UNFITIND-HSTCL-1L-ICE-ALLOSCT- IND-HSTCL-1L-ICE-ALLOSCT
Questionnaires
QUEST-HSTCL-1L-STUB- Hepatosplenic T-Cell Lymphoma — first line
Red flag
RF-HSTCL-FRAILTY-AGE- Age >65 OR ECOG ≥3 — ICE + alloSCT toxicity prohibitive; reduced-intensity conditioning a...RF-HSTCL-HIGH-RISK-BIOLOGY- γδ T-cell receptor variant (most common) vs αβ variant — both aggressive but γδ classical...RF-HSTCL-INFECTION-SCREENING- EBV / HBV / HCV / CMV / Strongyloides screen pre-induction; HSTCL is rare in immunocompet...RF-HSTCL-ORGAN-DYSFUNCTION- Hepatic dysfunction (Child-Pugh B/C, bilirubin >3xULN) at HSTCL diagnosis — disease itsel...RF-HSTCL-TRANSFORMATION-PROGRESSION- Refractory or rapid-relapse disease post-ICE — alloSCT urgently if not yet planned; other...RF-IATROGENIC-ANTI-TNF-LYMPHOMA-PREVENTION- Chronic anti-TNF biologic exposure ≥3 years in pediatric, adolescent, or young-adult infl...
Sources
SRC-ESMO-PTCL-2024- ESMO Clinical Practice Guideline on Peripheral T-cell Lymphomas